Drug discovery group Immupharma fell into losses in the year to 31 December, but pointed to progress with its ongoing trials.Pre-tax losses totalled £2m for the year, against a profit of £9.1m the previous year. Revenues fell to just £325,000 from £22.05m. "Early results of our cancer programme are encouraging, and we look forward to reporting on further developments during 2011," chairman Richard Warr said.RG